Limited Mobile Version
Follow this company and never miss a research update
NVP

Neurovive Pharmaceutical

Market Cap 301.8M
Today
Day High
7.90
6.1
Day Low
4.14
Day Open
4.19
Prev Close
4.19
VWAP
6.6
Volume
6,543K
Turnover
43.138M
Top Broker
AVA
VWAP
4.3
Avg Volume
264K
Avg Turnover
1.149M
Top Brokers
AVA/NON
VWAP
4.2
Avg Volume
207K
Avg Turnover
0.873M
Top Brokers
AVA/NON
VWAP
4.1
Avg Volume
147K
Avg Turnover
0.606M
Top Brokers
AVA/NON
52 week summary
Price Range
2.9
Last
7.9
Beta
N/A
Market Cap
301.8M
Total Return
-4.8%
Trailing P/E
N/A
Div Yield
N/A%
Shares Outstanding
49.5M
Next Earnings Date
17 Aug
Stock Exchange
NASDAQ Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.


Relative Price Strength
Change 3 Months -5.4%
Change 12 Months -26.4%
Volume Trend
Average Volume 10 vs 60 Days 35.8%
Price VS
52 Week High -22.8%
50 Day Moving Average 57.7%
200 Day moving Average 40.8%

Add article markers

Compare Neurovive Pharmaceutical to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • Erik Kinnman, CEO
  • Executive board
  • Gregory Batcheller, Chairman of the board
Source: Millistream
Major Owners Equity Votes
Försäkringsaktiebolaget, Avanza Pension 11.4%
11.4%
Euroclear Bank S.A/N.V, W8-IMY 9.0%
9.0%
Baulos Capital Belgium SA 8.8%
8.8%
Danske Bank International 3.4%
3.4%
Nordnet Pensionförsäkring 2.5%
2.5%
Source: Millistream
Timeframe Transactions Net Shares
Last 12 weeks
0 Purchases
+ 0
0 Sales
- 0
Last 24 weeks
0 Purchases
+ 0
0 Sales
- 0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Catalyst Potential is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Sign up Login
Source: Millistream FI
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Sign up Login
Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.


Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.